ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Salt Lake City, UT, USA:

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 209 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 242 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Salt Lake City, Utah, United States and 14 other locations

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Salt Lake City, Utah, United States and 117 other locations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Phase 3

AbbVie
AbbVie

Ogden, Utah, United States and 298 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC)....

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Salt Lake City, Utah, United States and 30 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Salt Lake City, Utah, United States and 347 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Ca...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Salt Lake City, Utah, United States and 207 other locations

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) ca...

Enrolling
Non-Small Cell Lung Cancer
EGFR/HER2 Exon 20 Insertion Mutation
Drug: STX-721 (3 dose levels)
Drug: STX-721 (Escalated)

Phase 1, Phase 2

Antares Therapeutics, Inc

Salt Lake City, Utah, United States and 19 other locations

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 242 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems